Overview
The goal of this clinical trial is to improve patient care after acute kidney injury (AKI). It has three related parts. The main questions it aims to answer are:
- Is creatinine or cystatin a more reliable assessment of kidney function after AKI?
- What are the experiences of patients after AKI?
- What interventions should be recommended to improve assessment and support of patients after AKI?
Participants will be asked to do one or more of:
- blood tests to measure kidney function in different ways
- have measurement of their body composition
- complete questionnaires about their symptoms
- have an interview with a researcher about their experiences
- discussion to develop an action plan based on findings
Eligibility
- Known or suspected pancreas disease including:
- pancreas adenocarcinoma
- islet cell cancer
- pancreatic cysts
- pancreatitis (hereditary, acute, or chronic)
- Next of kin of deceased participant who did not complete participation before passing away
Exclusion Criteria:
- Under the age of 18
- Unable to provide informed consent
- Prison inmates
